Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Medicare fully reimburses EsoGuard nationwide at $1,938.01 per test.
- ➤Lucid performed 2,871 EsoGuard tests, generating $1.2 million revenue in 3Q26.
- ➤October EsoGuard volume exceeded 1,800 tests, setting a monthly record.
- ➤Operating expenses reached $13.5 million; GAAP net loss was $6.7 million.
- ➤Lucid closed a $15.0 million Series C Convertible Preferred Stock financing.
Expert Statements
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“Our pursuit of EsoGuard's enormous clinical and commercial opportunity is now substantially less constrained by external factors.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“Lucid's near-term growth now depends almost entirely on our team's commercial and operational execution.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid Diagnostics
“What has been a marathon is now a sprint.”
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results PR Newswire
EsoGuard(®) now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter
Get started
Create a free account to read the full story.